Eton Pharmaceuticals ( (ETON) ) has released its Q4 earnings. Here is a breakdown of the information Eton Pharmaceuticals presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with a strong emphasis on pediatric endocrinology and metabolic conditions.
In its fourth quarter of 2024, Eton Pharmaceuticals reported record product revenue of $11.6 million, marking a 59% increase over the same period in 2023. This quarter was highlighted by the acquisition and relaunch of Increlex® and Galzin®, as well as the licensing of Amglidia® to enhance its pediatric endocrinology pipeline.
Key financial metrics include a gross profit of $6.5 million, up from $3.6 million in the previous year, driven by strong sales of ALKINDI SPRINKLE® and Carglumic Acid. The company also reported a net loss of $0.6 million, a significant improvement from the $2.3 million loss in the prior year. Strategic developments included the successful pivotal study results for ET-600 and preparation for the potential launch of ET-400.
Eton Pharmaceuticals is optimistic about its growth prospects in 2025, with the relaunch of Increlex® and Galzin® already exceeding expectations. The company is preparing for the potential approval and launch of ET-400 by May 28, 2025, and plans to submit an NDA for ET-600 in April 2025, aiming for approval in early 2026.